Max Bayer is a Pharma Reporter at Endpoints News. He covers a range of topics within the healthcare sector, focusing on pharmaceuticals, healthcare administration, and the emerging fields of psychedelic research and therapy. His work has been featured in notable publications such as Biotech, Fierce Pharma, and Endpoints News.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
United States (National)
Not enough data
Max Bayer's coverage primarily focuses on the healthcare and pharmaceutical industry, specifically on biotech, drug development, FDA approvals, and clinical trials. His articles often contain press releases and cite data from private sector announcements.
To effectively reach out to Max Bayer, consider providing pitches related to groundbreaking advancements in biotechnology or pharmaceuticals with a focus on new drug applications, significant leadership changes within prominent companies in the industry, as well as noteworthy partnerships or deals between key players. Additionally, offering insights supported by reliable data could enhance the appeal of your pitch.
Given that Max Bayer does not have a specific geographic focus mentioned but covers global developments within the healthcare and pharmaceutical sectors, ensure that your pitches reflect international relevance rather than being region-specific.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Max Bayer
Anxiously awaiting an FDA decision this fall, Beren Therapeutics has added $300 million in new capital to help launch its rare disease drug.
By: Max Bayer, Alex Hoffman, Kyle Lahucik
The Dutch investment firm has scooped up Novo Nordisk’s head of M&A John McDonald as operating partner of business development and M&A.
We value your privacy We use cookies to enhance your browsing experience and analyze our traffic. By selecting “Accept All”, you consent to our use of cookies.
By: Max Bayer
We value your privacy We use cookies to enhance your browsing experience and analyze our traffic. By selecting “Accept All”, you consent to our use of cookies.
By: Max Bayer, Alex Hoffman
→ In preparation for potential new product launches, Moderna has selected Ester Banque as chief commercial officer and expanded the role of president Stephen Hoge …
By: Max Bayer
We value your privacy We use cookies to enhance your browsing experience and analyze our traffic. By selecting “Accept All”, you consent to our use of cookies.
By: Max Bayer
Every member of a vaccine advisory panel for the FDA voted in favor of Moderna’s flu vaccine, after the product faced roadblocks from previous agency leadership.
By: Max Bayer
HHS launches clinical trial reforms — including new pilot programs and updated FDA guidance — to accelerate US drug development and compete with China.
By: Max Bayer
BIO makes China political strategy a top priority as US weighs outbound investment limits; CEO Crowley says biotech may fall under COINS Act.
By: Max Bayer
Three acting FDA leaders at BIO pitch rare disease framework and 2,200-hire rebuilding plan as agency works to restore trust post-Makary.
